Nasdaq · Healthcare
NEPHROS INC (NEPH)
As-reported financials and recent SEC filings for NEPHROS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$18.8M
Net income
$1.2M
Net margin
6.4%
Diluted EPS
$0.11
ROE
11.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $18.8M | $14.2M | $14.2M | $10.0M | $10.2M |
| Gross profit | $11.6M | $8.7M | $8.4M | $4.7M | $5.6M |
| Operating income | $1.1M | $6,000 | $-1.6M | $-4.3M | $-3.3M |
| Net income | $1.2M | $74,000 | $-1.6M | $-7.1M | $-3.9M |
| Diluted EPS | $0.11 | $0.01 | $-0.15 | $-0.73 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-15
View on EDGAR →42026-06-12
View on EDGAR →8-K2026-05-07
View on EDGAR →10-Q2026-05-07
View on EDGAR →10-K/A2026-04-30
View on EDGAR →8-K2026-03-27
View on EDGAR →42026-03-25
View on EDGAR →42026-03-25
View on EDGAR →Largest Healthcare peers
Go deeper on NEPH
Search NEPHROS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.